Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Laronib 25
Everest Pharmaceuticals Ltd.
Generic: Larotrectinib
Medicine Overview of Laronib 25mg Capsule
বাংলা
English
Indication
Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment
Administration
Capsules or oral solution may be used interchangeably
Adult Dose
Solid Tumors
Indicated for treatment of patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment
100 mg PO BID
Continue until disease progression or until unacceptable toxicity
Hepatic impairment
Mild (Child-Pugh A): No dosage adjustment necessary
Moderate to severe (Child-Pugh B or C): Reduce starting dose by 50%
Child Dose
Solid Tumors
Indicated for treatment of patients with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment
Body surface area (BSA) 1 m²: 100 mg PO BID
Continue until disease progression or until unacceptable toxicity
Renal Dose
Renal impairment
Mild to severe: No dosage adjustment necessary
Mode of Action
Highly selective inhibitor of tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC
TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3; chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and survival in tumor cell lines
In tumor models, larotrectinib demonstrates antitumor activity in cells by activation of TRK proteins resulting from gene fusions, deletion of a protein regulatory domain, or in cells with TRK overexpression
Precaution
Neurologic adverse reactions (any grade) occurred; majority of neurologic adverse reactions occurred within first 3 months of treatment; advise patients not to drive or operate hazardous machinery if they are experiencing neurologic adverse reactions
Increased transaminases of any grade occurred; median time to onset of increased AST/ALT was 2 months; monitor liver tests every 2 weeks during first month of treatment, then monthly thereafter, and as clinically indicated
Can cause fetal harm when administered to pregnant women
Side Effect
>10% Increased AST/ALT (45%) Anemia (42%) Fatigue (37%) Hypoalbuminemia (35%) Increased alkaline phosphatase (30%) Nausea (29%) Dizziness (28%) Vomiting (26%) Cough (26%) Constipation (23%) Neutropenia (23%) Diarrhea (22%) Pyrexia (18%) Dyspnea (18%) Peripheral edema (15%) Increased weight (15%) Headache (14%) Arthralgia (14%) Myalgia (14%) Muscular weakness (13%) Decreased appetite (13%) Abdominal pain (13%) Back pain (12%) Pain in extremity (12%) Hypertension (11%) 1-10% Nasal congestion (10%) Fall (10%) Anemia, Grade 3 or 4 (10%) Neutropenia, Grade 3 or 4 (7%) Increased weight, Grade 3 or 4 (4%) Fatigue, Grade 3 or 4 (3%) Increased alkaline phosphatase, Grade 3 or 4...
... Show morePregnancy Category Note
Pregnancy Based on literature reports, findings from animal studies, and its mechanism of action, embryo-fetal harm may occur when administered to a pregnant woman There are no available data on use in pregnant women Verify pregnancy status in females of reproductive potential prior to initiation Animal data Administration of larotrectinib to pregnant rats and rabbits during organogenesis resulted in malformations at maternal exposures were ~11- and 0.7-times (observed at 100 mg PO BID) Contraception Females of reproductive potential: Advise to use of effective contraception during treatment and for at least 1 week after last dose Males: Advise males with female...
... Show moreInteraction
Larotrectinib is a substrate of CYP3A4 (major); also a P-gp and BCRP substrate Larotrectinib moderately inhibits CYP3A4 Strong CYP3A4 inhibitors Coadministration with a strong CYP3A4 inhibitor may increase larotrectinib plasma concentrations and potentially result in higher incidence of adverse reactions Avoid use with strong CYP3A4 inhibitors, including grapefruit or grapefruit juice; if coadministration of strong CYP3A4 inhibitors cannot be avoided, modify dose as recommended Strong CYP3A4 inducers Coadministration with a strong CYP3A4 inducer may decrease larotrectinib plasma concentrations, which may decrease efficacy Avoid use with strong CYP3A4 inducers; if coadministration of strong CYP3A4 inducers cannot be avoided, modify dose as...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register